Lilly Receives Additional FDA Approval for Verzenio (abemaciclib), as Initial Treatment for Advanced Breast Cancer

INDIANAPOLIS, Feb. 26, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved Verzenio (abemaciclib) in combination with an aromatase inhibitor (AI) as initial...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news